New York has built gleaming new research facilities and lured at least one large drug company, but the city still trails places such as Boston and San Francisco in fostering small companies that experiment with cutting-edge medical treatments.
To help the local biotechnology scene catch up, the Bloomberg administration is working with large pharmaceutical companies and venture capitalists to create a $100 million fund to invest in fledgling life sciences companies.
{iframe}http://online.wsj.com/news/articles/SB10001424052702304355104579236310004192826{/iframe}